Danish pharmaceutical giant Novo Nordisk has announced it will significantly reduce prices for its popular weight-loss medications Wegovy and Ozempic in the United States, according to reports from Wall Street Journal. The company plans to implement price reductions of up to 50 percent starting in January 2027. Both medications, which have gained widespread popularity for weight management and diabetes treatment, will become more accessible to American consumers under the new pricing structure.
The announcement represents a major shift in pricing strategy for the pharmaceutical company, which has faced scrutiny over the high costs of its GLP-1 receptor agonist medications. The price cuts are expected to make these treatments more affordable for patients who have struggled with insurance coverage and out-of-pocket expenses.